Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma
About this trial
This is an interventional diagnostic trial for Stage IA Non-Small Cell Lung Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Biopsy proven non-small cell lung cancer
- Minimum tumor dimension >= 1 cm (preferably >= 2 cm)
- No clinical evidence of nodal disease (N1-N3) as assessed by CT and/or positron emission tomography (PET)/CT
- Zubrod performance status 0-2
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
- No prior radiation to the same area
- No concurrent chemotherapy
- Evaluated by radiation oncologist to be appropriate SBRT candidate and scheduled to undergo SBRT as part of their care
- Ability to understand and the willingness to sign a written informed consent
Exclusion Criteria:
- Patients with tumors < 1 cm
- Patients with nodal disease or distant metastatic disease
- Patients may not be receiving any other investigational agents
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients must not be pregnant
- Patients with allergies to iodinated contrast not amenable to pre-medication
- Patients who are not able to lie supine with arms raised, and cooperate with breathholding instructions
Sites / Locations
- USC / Norris Comprehensive Cancer Center
Arms of the Study
Arm 1
Experimental
Diagnostic (DPCT)
Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.